{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:37:10Z","timestamp":1790671030127,"version":"4.1.0"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>An interstitial deletion on chromosome 4q12 resulting in the formation of the FIP1L1-PDGFRA fusion protein is involved in the pathogenesis of imatinib-sensitive chronic eosinophilic leukemia. The molecular mechanisms underlying the development of disease are largely undefined. Human CD34+ hematopoietic progenitor cells were used to investigate the role of FIP1L1-PDGFRA in modulating lineage development. FIP1L1-PDGFRA induced both proliferation and differentiation of eosinophils, neutrophils, and erythrocytes in the absence of cytokines, which could be inhibited by imatinib. Whereas expression of FIP1L1-PDGFRA in hematopoietic stem cells and common myeloid progenitors induced the formation of multiple myeloid lineages, expression in granulocyte-macrophage progenitors induced only the development of eosinophils, neutrophils, and myeloblasts. Deletion of amino acids 30 to 233 in the FIP1L1 gene [FIP1L1(1\u201329)-PDGFRA] gave rise to an intermediate phenotype, exhibiting a dramatic reduction in the number of erythrocytes. FIP1L1-PDGFRA and FIP1L1(1\u201329)-PDGFRA both induced the activation of p38 and extracellular signal-regulated kinase 1\/2 (ERK1\/2) in myeloid progenitors, whereas signal transducers and activators of transcription 5 (STAT5) and protein kinase B\/c-akt were only activated by FIP1L1-PDGFRA. Dominant-negative STAT5 partially inhibited FIP1L1-PDGFRA\u2013induced colony formation, whereas combined inhibition of phosphatidylinositol-3-kinase and ERK1\/2 significantly reversed FIP1L1-PDGFRA\u2013induced colony formation. Taken together, these results suggest that expression of FIP1L1-PDFGRA in human hematopoietic progenitors induce a myeloproliferative phenotype via activation of multiple signaling molecules including phosphatidylinositol-3-kinase, ERK1\/2, and STAT5. [Cancer Res 2007;67(8):3759\u201366]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-4183","type":"journal-article","created":{"date-parts":[[2007,4,17]],"date-time":"2007-04-17T18:39:26Z","timestamp":1176835166000},"page":"3759-3766","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Molecular Mechanisms Underlying FIP1L1-PDGFRA\u2013Mediated Myeloproliferation"],"prefix":"10.1158","volume":"67","author":[{"given":"Miranda","family":"Buitenhuis","sequence":"first","affiliation":[{"name":"1Molecular Immunology Lab, Department of Immunology, University Medical Center, Utrecht, the Netherlands and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth P.","family":"Verhagen","sequence":"additional","affiliation":[{"name":"1Molecular Immunology Lab, Department of Immunology, University Medical Center, Utrecht, the Netherlands and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Cools","sequence":"additional","affiliation":[{"name":"2Department of Human Genetics, Flanders Interuniversity Institute for Biotechnology (VIB), University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Coffer","sequence":"additional","affiliation":[{"name":"1Molecular Immunology Lab, Department of Immunology, University Medical Center, Utrecht, the Netherlands and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,4,17]]},"reference":[{"key":"2022061623200090500_B1","doi-asserted-by":"crossref","unstructured":"Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore)\u20081975; 54: 1\u201327.","DOI":"10.1097\/00005792-197501000-00001"},{"key":"2022061623200090500_B2","doi-asserted-by":"crossref","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med\u20082003; 348: 1201\u201314.","DOI":"10.1056\/NEJMoa025217"},{"key":"2022061623200090500_B3","doi-asserted-by":"crossref","unstructured":"Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia\u20082004; 18: 734\u201342.","DOI":"10.1038\/sj.leu.2403313"},{"key":"2022061623200090500_B4","unstructured":"La SR, Specchia G, Cuneo A, et al. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1\/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica\u20082005; 90: 596\u2013601."},{"key":"2022061623200090500_B5","doi-asserted-by":"crossref","unstructured":"Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia\u20082005; 19: 792\u20138.","DOI":"10.1038\/sj.leu.2403722"},{"key":"2022061623200090500_B6","doi-asserted-by":"crossref","unstructured":"Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood\u20082004; 104: 3038\u201345.","DOI":"10.1182\/blood-2004-03-0787"},{"key":"2022061623200090500_B7","doi-asserted-by":"crossref","unstructured":"Gotlib J, Cools J, Malone JM III, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFR\u03b1 fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood\u20082004; 103: 2879\u201391.","DOI":"10.1182\/blood-2003-06-1824"},{"key":"2022061623200090500_B8","doi-asserted-by":"crossref","unstructured":"Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res\u20082002; 26: 881\u20134.","DOI":"10.1016\/S0145-2126(02)00046-2"},{"key":"2022061623200090500_B9","doi-asserted-by":"crossref","unstructured":"Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet\u20082002; 359: 1577\u20138.","DOI":"10.1016\/S0140-6736(02)08505-7"},{"key":"2022061623200090500_B10","doi-asserted-by":"crossref","unstructured":"Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood\u20082003; 101: 4714\u20136.","DOI":"10.1182\/blood-2003-01-0081"},{"key":"2022061623200090500_B11","unstructured":"Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res\u20081996; 56: 100\u20134."},{"key":"2022061623200090500_B12","doi-asserted-by":"crossref","unstructured":"Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood\u20082000; 96: 925\u201332.","DOI":"10.1182\/blood.V96.3.925"},{"key":"2022061623200090500_B13","doi-asserted-by":"crossref","unstructured":"Taylor JR, Brownlow N, Domin J, Dibb NJ. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene\u20082006; 25: 147\u201351.","DOI":"10.1038\/sj.onc.1209007"},{"key":"2022061623200090500_B14","doi-asserted-by":"crossref","unstructured":"Yamada Y, Rothenberg ME, Lee AW, et al. The FIP1L1-PDGFR{\u03b1} fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)\/chronic eosinophilic leukemia (CEL)-like disease. Blood\u20082006; 107: 4071\u20139.","DOI":"10.1182\/blood-2005-08-3153"},{"key":"2022061623200090500_B15","doi-asserted-by":"crossref","unstructured":"Stover EH, Chen J, Folens C, et al. Activation of FIP1L1-PDGFR\u03b1 requires disruption of the juxtamembrane domain of PDGFR\u03b1 and is FIP1L1-independent. Proc Natl Acad Sci U S A\u20082006; 103: 8078\u201383.","DOI":"10.1073\/pnas.0601192103"},{"key":"2022061623200090500_B16","doi-asserted-by":"crossref","unstructured":"Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A\u20082002; 99: 11872\u20137.","DOI":"10.1073\/pnas.172384399"},{"key":"2022061623200090500_B17","doi-asserted-by":"crossref","unstructured":"Sanderson CJ, Warren DJ, Strath M. Identification of a lymphokine that stimulates eosinophil differentiation in vitro. Its relationship to interleukin 3, and functional properties of eosinophils produced in cultures. J Exp Med\u20081985; 162: 60\u201374.","DOI":"10.1084\/jem.162.1.60"},{"key":"2022061623200090500_B18","doi-asserted-by":"crossref","unstructured":"Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med\u20081989; 169: 1721\u201331.","DOI":"10.1084\/jem.169.5.1721"},{"key":"2022061623200090500_B19","doi-asserted-by":"crossref","unstructured":"Moriggl R, Gouilleux-Gruart V, Jahne R, et al. Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype. Mol Cell Biol\u20081996; 16: 5691\u2013700.","DOI":"10.1128\/MCB.16.10.5691"},{"key":"2022061623200090500_B20","doi-asserted-by":"crossref","unstructured":"Buitenhuis M, Baltus B, Lammers JW, Coffer PJ, Koenderman L. Signal transducer and activator of transcription 5a (STAT5a) is required for eosinophil differentiation of human cord blood-derived CD34+ cells. Blood\u20082003; 101: 134\u201342.","DOI":"10.1182\/blood-2002-03-0740"},{"key":"2022061623200090500_B21","doi-asserted-by":"crossref","unstructured":"Schuringa JJ, Chung KY, Morrone G, Moore MA. Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J Exp Med\u20082004; 200: 623\u201335.","DOI":"10.1084\/jem.20041024"},{"key":"2022061623200090500_B22","doi-asserted-by":"crossref","unstructured":"Onishi M, Nosaka T, Misawa K, et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol\u20081998; 18: 3871\u20139.","DOI":"10.1128\/MCB.18.7.3871"},{"key":"2022061623200090500_B23","doi-asserted-by":"crossref","unstructured":"Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood\u20082003; 101: 4660\u20136.","DOI":"10.1182\/blood-2003-01-0006"},{"key":"2022061623200090500_B24","doi-asserted-by":"crossref","unstructured":"Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood\u20082003; 102: 3093\u20136.","DOI":"10.1182\/blood-2003-05-1627"},{"key":"2022061623200090500_B25","doi-asserted-by":"crossref","unstructured":"Robyn J, Lemery S, McCoy JP, et al. Multilineage involvement of the fusion gene in patients with FIP1L1\/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol\u20082006; 132: 286\u201392.","DOI":"10.1111\/j.1365-2141.2005.05863.x"},{"key":"2022061623200090500_B26","doi-asserted-by":"crossref","unstructured":"Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature\u20082006; 442: 818\u201322.","DOI":"10.1038\/nature04980"},{"key":"2022061623200090500_B27","doi-asserted-by":"crossref","unstructured":"Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer\u20082004; 100: 116\u201321.","DOI":"10.1002\/cncr.11863"},{"key":"2022061623200090500_B28","doi-asserted-by":"crossref","unstructured":"Appel S, Boehmler AM, Grunebach F, et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood\u20082004; 103: 538\u201344.","DOI":"10.1182\/blood-2003-03-0975"},{"key":"2022061623200090500_B29","doi-asserted-by":"crossref","unstructured":"Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood\u20082005; 105: 2473\u20139.","DOI":"10.1182\/blood-2004-07-2527"},{"key":"2022061623200090500_B30","doi-asserted-by":"crossref","unstructured":"Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood\u20081997; 90: 3691\u20138.","DOI":"10.1182\/blood.V90.9.3691"},{"key":"2022061623200090500_B31","doi-asserted-by":"crossref","unstructured":"Bartolovic K, Balabanov S, Hartmann U, et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood\u20082004; 103: 523\u20139.","DOI":"10.1182\/blood-2003-05-1535"},{"key":"2022061623200090500_B32","doi-asserted-by":"crossref","unstructured":"Bujis A, Bruin M. Fusin of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia. Leukemia 2007, in press.","DOI":"10.1038\/sj.leu.2404596"},{"key":"2022061623200090500_B33","doi-asserted-by":"crossref","unstructured":"Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet\u20082006; 7: 606\u201319.","DOI":"10.1038\/nrg1879"},{"key":"2022061623200090500_B34","doi-asserted-by":"crossref","unstructured":"Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res\u20082002; 12: 9\u201318.","DOI":"10.1038\/sj.cr.7290105"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/8\/3759\/2581933\/3759.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/8\/3759\/2581933\/3759.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:29:17Z","timestamp":1655432957000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/8\/3759\/534906\/Molecular-Mechanisms-Underlying-FIP1L1-PDGFRA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,15]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2007,4,17]]},"published-print":{"date-parts":[[2007,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-4183","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,15]]}}}